Long Term Follow-up Study to Evaluate the Safety of Repeated Intra-Articular Injection of SI-613 in Patients with Osteoarthritis.
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 10 Sep 2018
Price : $35 *
At a glance
- Drugs Diclofenac-Eatlhyaluronate (Primary)
- Indications Osteoarthritis
- Focus Adverse reactions
- Sponsors Ono Pharmaceutical; Seikagaku Corporation
- 06 Sep 2018 Status changed from recruiting to active, no longer recruiting.
- 08 Feb 2018 New trial record